中閩能源(600163.SH):2021年度發電量升18.15%至27.22億千瓦時
格隆匯1月14日丨中閩能源(600163.SH)公佈2021年度發電量完成情況,公司統計,2021年度公司下屬各項目累計完成發電量27.22億千瓦時,比去年同期230,417.64萬千瓦時增長18.15%;累計完成上網電量265,389.28萬千瓦時,比去年同期223,987.58萬千瓦時增長18.48%。
公司本期電量較去年同期增加的主要原因為:馬頭山風電場、王母山風電場、大帽山風電場、青峯風電場二期項目於2020年陸續建成投產,2021年前述項目全年全容量併網發電;平海灣海上風電場二期項目於2021年12月21日實現全容量併網發電,併網風機數量較去年同期增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.